Medicis Announces Third Quarter Fiscal 2001 Conference Call and Webcast
SCOTTSDALE, Ariz.--April 16, 2001--Medicis Pharmaceutical Corporation (NYSE:MRX) today announced it will report third quarter fiscal 2001 financial results after the market closes on Thursday, April 19, 2001.
The Company will host a conference call at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) to review the March 31, 2001 third quarter financial results, as well as provide an update on other business matters of the Company. A live webcast will also be available at http://www.medicis.com. The webcast will be archived on the Company's web site for two business days following the live call.
Interested participants should contact Medicis Investor Relations at (602) 808-3854 or investor_relations@medicis.com to reserve a line on the call. Callers should dial in approximately 10 minutes prior to the start of the call. A certain number of lines will be reserved based upon registrations.
The phone number to join the conference call is (719) 457-2633 for both domestic and international callers. No access code is necessary for the live call. For investors unable to participate in the live call, a replay will be available soon after the live call. The phone number to access the replay is (719) 457-0820 and the access code is 738611. The replay will be available for two business days following the live call.
Medicis is the leading independent pharmaceutical company in the United States focusing primarily on the treatment of dermatological conditions. Medicis develops and markets leading products for major segments within dermatology including acne, fungal infections, psoriasis, eczema, rosacea, seborrheic dermatitis, head lice and cosmesis (improvement in the texture and appearance of skin). Primary products include the prescription brands DYNACIN(R) (minocycline HCl), TRIAZ(R) (benzoyl peroxide), LUSTRA(R) (hydroquinone), LOPROX(R) (ciclopirox), OVIDE(R) (malathion), PLEXION(TM) (sodium sulfacetamide/sulfur), LIDEX(R) (fluocinonide), SYNALAR(R) (fluocinolone acetonide), TOPICORT(R) (desoximetasone), NOVACET(R) (sodium sulfacetamide/sulfur) and A/T/S(R) (erythromycin); the over-the-counter brand ESOTERICA(R); and BUPHENYL(TM) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder.
Except for historical information, this news release contains certain forward-looking statements that involve risks and uncertainties which may cause actual results to differ materially from the statements made, including the Company's dependence on sales of key products, uncertainty of future financial results and fluctuations in operating results, dependence on the Company's acquisition strategy, new product introductions and other risks described from time to time in the Company's SEC filings. These forward-looking statements represent the judgment of the Company, as of the date of this release, and Medicis disclaims any intent or obligation to update these forward-looking statements.
NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company.
Contacts: Medicis Pharmaceutical Corporation, Scottsdale Libby Ivy, 602/808-3854